Cefaly, created by New York-based Cefaly Technology, is an electronic, battery-powered device that is placed on the forehead for 20 minutes a day. Cefaly sends small electrical impulses through the skin to desensitizes the trigeminal nerve and reduce the frequency of migraines.
The company just released a new version of the device that is three-quarters the size of the original, fits in the palm of one’s hand, is rechargeable and allows patients to control the intensity of the electrical pulses.
In a recent clinical trial of the updated device — called Cefaly 2 — 81 percent of patients reported a significant reduction in migraine attacks, while 75 percent showed a reduction in the use of migraine medications.
Cefaly 2 is currently available by prescription in the U.S. and costs $349.
More articles on medical devices:
FDA approves Abbott’s intraocular lenses to treat cataracts
FDA lauds potential of 3D printing for personalized medicine
How the pause in medical device taxes helps medtechs grow
